Open access · CC-BY
via OpenAlex
Low‐Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle‐Aged and Older Adults: Study Protocol for a Triple‐Blind, Randomised, Placebo‐Controlled Trial
Juliette Tavenier, Magnus Berglind, Line Fleischer Hach, Louise Westberg Strejby Christensen, Maria Jana Masarikova, Rafal Yahya, Mette Bendtz Lindstroem, Baker Nawfal Jawad, Anna Zatkova, Rikke Lundsgaard Nielsen, Helle Gybel Juul‐Larsen, Thomas Kallemose, Jan Olof Nehlin, Morten Baltzer Houlind, Ove Andersen
Basic & Clinical Pharmacology & Toxicology · 2026
Cellular senescence
Chronic inflammation
Senolytics
Cell culture / in vitro
Human
Randomized controlled trial
In vitro
Abstract
Systemic chronic inflammation contributes to the development of many age-related chronic diseases and represents a promising target for interventions aiming at promoting healthy aging. Fisetin is a naturally occurring flavonoid with anti-inflammatory, antioxidant and senolytic effects in vitro and in animal models, but evidence from randomised controlled trials in humans is limited. This study is a triple-blind, randomised, placebo-controlled trial designed to investigate the association between daily fisetin supplementation and changes in plasma soluble urokinase plasminogen activator receptor (suPAR) levels, as well as the occurrence and severity of adverse events, in generally healthy middle-aged and older adults, with exploratory evaluation of additional biomarkers and functional outcomes. Participants aged ≥ 50 will be randomised to receive 100 mg of oral fisetin or placebo once daily for 7 weeks. The primary outcome is the between-group difference in the change in plasma levels of suPAR from Baseline to Week 7. The secondary outcome is the between-group difference in the occurrence and severity of adverse events during the study period. In addition, exploratory outcomes will evaluate the association of fisetin supplementation with other soluble and cellular biomarkers of inflammation, aging and cellular senescence(definition), as well as measures of frailty, physical and cognitive function and subjective health.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/bcpt.70290
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Tavenier, J., Berglind, M., Hach, L.F., Christensen, L.W.S., Masarikova, M.J., Yahya, R., Lindstroem, M.B., Jawad, B.N., Zatkova, A., Nielsen, R.L., Juul‐Larsen, H.G., Kallemose, T., Nehlin, J.O., Houlind, M.B., Andersen, O., & Rasmussen, L.J.H. (2026). Low‐Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle‐Aged and Older Adults: Study Protocol for a Triple‐Blind, Randomised, Placebo‐Controlled Trial. <em>Basic & Clinical Pharmacology & Toxicology</em>. https://doi.org/10.1111/bcpt.70290
Vancouver
Tavenier J, Berglind M, Hach LF, Christensen LWS, Masarikova MJ, Yahya R, et al. Low‐Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle‐Aged and Older Adults: Study Protocol for a Triple‐Blind, Randomised, Placebo‐Controlled Trial. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70290.
BibTeX
@article{juliette2026LowDos,
title = {Low‐Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle‐Aged and Older Adults: Study Protocol for a Triple‐Blind, Randomised, Placebo‐Controlled Trial},
author = {Juliette Tavenier and Magnus Berglind and Line Fleischer Hach and Louise Westberg Strejby Christensen and Maria Jana Masarikova and Rafal Yahya and Mette Bendtz Lindstroem and Baker Nawfal Jawad and Anna Zatkova and Rikke Lundsgaard Nielsen and Helle Gybel Juul‐Larsen and Thomas Kallemose and Jan Olof Nehlin and Morten Baltzer Houlind and Ove Andersen and Line Jee Hartmann Rasmussen},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
doi = {10.1111/bcpt.70290},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Elsevier eBooks 2025
Citation only
Inflammation: chronic inflammation in aging
Ove Andersen 2025
Open access · US-GOV
Low-dose Fisetin Supplementation for Healthy Aging - a Triple-blind, Randomized, Placebo-controlled Trial
Chang Gung Memorial Hospital 2024
Open access · US-GOV
Effects of "Comprehensive Health Promotion and Healthy Lifestyle Development" in Community-dwelling Elderly.
University of Florida 2014
Open access · US-GOV
Efficacy of Fermented Papaya Preparation on Markers of Systemic Inflammation
Dr. Chris McGlory, PhD 2025
Open access · US-GOV
Effects of Polyphenol Supplementation and Exercise on Physical Performance in Older Adults: A Randomized Controlled Pilot Feasibility Trial
Molecular Nutrition & Food Research 2016
Open access · OA